%0 Journal Article
%@ 1929-0748
%I JMIR Publications
%V 8
%N 1
%P e11911
%T Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial
%A Kromer,Christian
%A Nühnen,Viktoria P
%A Pfützner,Wolfgang
%A Pfeiffer,Sebastian
%A Laubach,Hans-Joachim
%A Boehncke,Wolf-Henning
%A Liebmann,Joerg
%A Born,Matthias
%A Schön,Michael P
%A Buhl,Timo
%+ Department of Dermatology, Venereology, and Allergology, University Medical Centre Göttingen, Robert-Koch-Strasse 40, Göttingen,, Germany, 49 55139 ext 66402, timo.buhl@med.uni-goettingen.de
%K atopic dermatitis
%K atopic eczema
%K blue light
%K irradiation
%K ultraviolet light
%D 2019
%7 08.01.2019
%9 Protocol
%J JMIR Res Protoc
%G English
%X Background: Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis. Objective: We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis. Methods: We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland). Results: The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte). Conclusions: We will disseminate the results in a peer-reviewed journal. Trial Registration: ClinicalTrials.gov NCT03085303; https://clinicaltrials.gov/ct2/show/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1) International Registered Report Identifier (IRRID): DERR1-10.2196/11911 
%M 30622089
%R 10.2196/11911
%U http://www.researchprotocols.org/2019/1/e11911/
%U https://doi.org/10.2196/11911
%U http://www.ncbi.nlm.nih.gov/pubmed/30622089